BCM
ITCI

BlueCrest Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

BlueCrest Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-18,529
Closed -$292K – 1152
2017
Q3 		$292K Buy
+18,529
New +$272K 0.01% 643
2016
Q1 		– Sell
-3,854
Closed -$207K – 1165
2015
Q4 		$207K Buy
+3,854
New +$194K 0.01% 856

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlueCrest Capital Management's ITCI Position: Q4 2017 in Review

BlueCrest Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2017, closing a stake of 18,529 shares — an estimated $292K sold.

BlueCrest Capital Management first reported a position in ITCI in Q4 2015 and held it in 2 quarters. The position peaked at $292K in Q3 2017. 131 funds tracked by Wall St. Rank hold ITCI as of Q4 2017.

  • BlueCrest Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2017 after selling out during the quarter.
  • BlueCrest Capital Management sold 18,529 Intra-Cellular Therapies Inc. shares in Q4 2017, an estimated $292K.
  • BlueCrest Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2015 and held it in 2 quarters.
  • BlueCrest Capital Management's Intra-Cellular Therapies Inc. position peaked at $292K in Q3 2017.
  • 131 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2017.

Based on BlueCrest Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.